Dalbavancin

TargetMol
Product Code: TAR-T21358
Supplier: TargetMol
CodeSizePrice
TAR-T21358-1mg1mg£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21358-5mg5mg£174.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21358-10mg10mg£227.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21358-1mL1 mL * 10 mM (in DMSO)£235.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21358-25mg25mg£386.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21358-50mg50mg£545.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T21358-100mg100mg£748.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Dalbavancin, a novel second-generation lipoglycopeptide antibiotic, possesses in vitro activity against a variety of Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE),Dalbavancin hydrochloride inhibits Staphylococcus aureus and Bacillus anthracis with MIC90s of 0.06 μg/mL and 0.25 μg/mL, respectively
CAS:
171500-79-1
Formula:
C88H101Cl3N10O28
Molecular Weight:
1853.17
Pathway:
Microbiology/Virology
Purity:
0.98
SMILES:
Cl.[H][C@@]12Cc3ccc(Oc4cc5cc(Oc6ccc(cc6Cl)[C@@H](O)[C@]6([H])NC(=O)[C@]([H])(NC(=O)[C@]5([H])NC(=O)[C@@]([H])(NC1=O)c1cc(Oc5cc(ccc5O)[C@@H](NC)C(=O)N2)cc(O)c1Cl)c1ccc(O)c(c1)-c1c(O[C@H]2O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]2O)cc(O)cc1[C@]([H])(NC6=O)C(=O)NCCCN(C)C)c4O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1NC(=O)CCCCCCCCC(C)C)C(O)=O)cc3
Target:
Antibacterial; Antibiotic

References

1. Scoble PJ, Owens RC Jr, Puttagunta S, Yen M, Dunne MW. Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese Subjects. Clin Drug Investig. 2015 Oct 12. [Epub ahead of print] PubMed PMID: 26458939. 2. Mendes RE, Castanheira M, Farrell DJ, Flamm RK, Sader HS, Jones RN. Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13). J Antimicrob Chemother. 2015 Oct 7. pii: dkv303. [Epub ahead of print] PubMed PMID: 26451012. 3. Lepak A, Marchillo K, VanHecker J, Andes D. Impact of Glycopeptide Resistance in Staphylococcus aureus on the Dalbavancin In Vivo Pharmacodynamic Target. Antimicrob Agents Chemother. 2015 Sep 21. pii: AAC.01717-15. [Epub ahead of print] PubMed PMID: 26392492. 4. Koeth LM, DiFranco-Fisher JM, McCurdy S. A Reference Broth Microdilution Method for Dalbavancin In Vitro Susceptibility Testing of Bacteria that Grow Aerobically. J Vis Exp. 2015 Sep 9;(103). doi: 10.3791/53028. PubMed PMID: 26381422.